Novo Nordisk Adds Chinese MASH Approval and Two EU Nods as London Strategy Day Looms

China clears Wegovy for MASH as EMA panel backs hemophilia A therapy FREHEMGO and weekly growth hormone Sogroya for children.

Novo Nordisk has picked up a trio of regulatory wins across two continents in the space of a week, strengthening its metabolic and rare-disease franchises just as management prepares to lay out a refreshed corporate roadmap in London.

China's drug regulator cleared Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), opening a new indication for the blockbuster GLP-1 therapy in the world's second-largest pharmaceutical market. The decision stretches the drug's label well beyond obesity treatment and hands the Danish group an additional revenue stream in a region where demand for metabolic medicines continues to build.

Brussels Delivers Back-to-Back Endorsements

The Chinese green light was followed by a pair of positive votes from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). On Thursday, the panel backed marketing authorization for FREHEMGO (denecimig) in hemophilia A for both adults and children. The therapy is the first FVIIIa mimetic to offer prophylaxis via a ready-to-use pen on a once-weekly, biweekly or monthly schedule.

Supporting data arrived the same day, with results from the Phase 3b FRONTIER5 study published in the Journal of Thrombosis and Haemostasis. The trial demonstrated favorable tolerability following a direct switch from emicizumab to denecimig, alongside sustained thrombin generation within the normal range. Novo Nordisk intends to launch FREHEMGO in the first European countries in the fourth quarter of 2026, widening the rollout across the EU from early 2027.

A day later, the CHMP recommended approval of the growth hormone Sogroya (somapacitan) for once-weekly treatment of children with idiopathic short stature. If the European Commission follows the recommendation — a decision is expected before the end of the year — it would become the first and only therapy specifically authorized for this indication in the EU.

Pipeline Push Extends Beyond the Lab

Novo Nordisk is not relying solely on internal programs. On Thursday it signed a research and licensing partnership with Orbis Medicines covering oral therapies for cardiometabolic disease, a deal carrying a potential total value of up to USD 1.4 billion. The company is also taking a direct equity stake in Orbis as part of a strategic investment.

Technology is another front. A collaboration unveiled Wednesday with Anthropic aims to apply artificial intelligence to drug-discovery bottlenecks, support scientific workflows and speed up the development of new medicines.

Investors will get a broader view of the pipeline at the EASD congress in Milan, running from September 28 to October 2, where new data on metabolic therapies is scheduled for presentation. Among the disclosures are findings on the Wegovy tablet and next-generation amylin compounds.

Rebranding and a Cultural Reset

The flurry of announcements coincides with an internal overhaul. Novo Nordisk has introduced a unified brand identity under the name "Novo" and the tagline "Lasting Health Starts Now," while the legal entity continues to operate as Novo Nordisk A/S. A revised internal culture strategy, dubbed "The Novo Way," was presented on Monday.

Chief executive Mike Doustdar pressed staff on Tuesday for a sharper customer focus, according to media reports, as the company works to recover ground lost in the obesity-medicine market.

Shares Reflect the Competitive Squeeze

The regulatory momentum has yet to translate into share-price strength. Novo Nordisk closed Friday at EUR 37.58, a modest decline of 0.3 percent on the day, and the stock has shed 15 percent since the start of the year. Analysts attribute the pullback to muted medium-term growth expectations and risks tied to patent expirations after 2030.

Monday's Capital Markets Day in London offers management a platform to address those concerns, with a detailed update on the revised corporate strategy on the agenda.